Estados financieros detallados de Design Therapeutics, Inc. (DSGN): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $12.51, DSGN presenta beneficios negativos (P/E no significativo) y un ROE del -34.03%. La capitalización bursátil es de $781M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Ingresos | $834 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $1654 | $5000 | 0 | $466000 | $537000 | $596000 | $622000 |
| Beneficio Bruto | -$820 | -$5000 | 0 | -$466000 | -$537000 | -$596000 | -$622000 |
| I+D | $1.7M | $6.1M | $24.8M | $48.6M | $57.1M | $44.4M | $59.1M |
| Generales y Administrativos | $1.1M | $2.5M | $11.1M | $19.0M | $21.1M | $18.0M | $20.3M |
| Gastos Operativos | $1.9M | $8.6M | $35.8M | $67.1M | $77.7M | $61.8M | $78.8M |
| Beneficio Operativo | -$1.9M | -$8.6M | -$35.8M | -$67.6M | -$78.2M | -$62.4M | -$79.5M |
| EBITDA | -$139000 | -$8.3M | -$35.4M | -$62.8M | -$66.3M | -$49.0M | -$69.2M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$2.0M | -$8.3M | -$35.5M | -$63.3M | -$66.9M | -$49.6M | -$69.8M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$2.0M | -$8.3M | -$35.5M | -$63.3M | -$66.9M | -$49.6M | -$69.8M |
| BPA | $-0.08 | $-0.30 | $-0.77 | $-1.14 | $-1.19 | $-0.88 | $-1.22 |
| BPA Diluido | $-0.08 | $-0.30 | $-0.77 | $-1.14 | $-1.19 | $-0.88 | $-1.22 |
| Acciones en Circulación (Diluidas) | $27.2M | $27.2M | $45.9M | $55.7M | $56.0M | $56.6M | $57.3M |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $77000 | $2.4M | $298.6M | $26.5M | $21.2M | $22.6M | $16.9M |
| Inversiones a Corto | 0 | $33.7M | $85.5M | $303.9M | $260.6M | $222.9M | $203.0M |
| Cuentas por Cobrar | 0 | $10000 | $110000 | $1.1M | $1.4M | $1.3M | $1.7M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $90000 | $36.2M | $385.4M | $335.1M | $284.6M | $248.0M | $223.8M |
| Inmovilizado Material | 0 | $71000 | $5.1M | $5.6M | $4.6M | $3.6M | $2.4M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $90000 | $36.5M | $390.6M | $341.1M | $289.6M | $252.1M | $226.2M |
| Cuentas por Pagar | $2.5M | $1.4M | $1.6M | $3.0M | $1.9M | $2.2M | $2.3M |
| Deuda a Corto | $695000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $3.7M | $2.3M | $5.3M | $10.8M | $9.6M | $8.5M | $13.1M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | $645000 |
| Pasivos Totales | $3.7M | $47.8M | $8.4M | $13.8M | $12.0M | $10.0M | $13.7M |
| Reservas | -$3.6M | -$11.9M | -$47.5M | -$110.8M | -$177.6M | -$227.2M | -$297.0M |
| Patrimonio Neto | -$3.6M | -$11.3M | $382.1M | $327.3M | $277.7M | $242.1M | $212.5M |
| Deuda Total | $695000 | 0 | $3.6M | $3.7M | $3.0M | $2.3M | $1.5M |
| Deuda Neta | $618000 | -$36.1M | -$380.4M | -$326.7M | -$278.7M | -$243.1M | -$218.3M |
| Capital Circulante | -$3.6M | $33.9M | $380.2M | $324.3M | $275.0M | $239.6M | $210.7M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$2.0M | -$8.3M | -$35.5M | -$63.3M | -$66.9M | -$49.6M | -$69.8M |
| Amortizaciones | 0 | $5000 | $129000 | $406000 | $537000 | $596000 | $622000 |
| Compensación en Acciones | 0 | $450000 | $4.7M | $10.9M | $13.1M | $13.1M | $14.5M |
| Cambio en Capital Circulante | $1.8M | -$811000 | $1.4M | $2.0M | $728000 | -$993000 | $3.1M |
| Flujo de Caja Operativo | -$139000 | -$8.7M | -$29.4M | -$51.3M | -$58.6M | -$43.1M | -$54.4M |
| Inversiones (CapEx) | 0 | -$76000 | -$1.5M | -$918000 | -$256000 | -$340000 | -$193000 |
| Adquisiciones | 0 | 0 | $52106 | $39000 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$139000 | -$8.7M | -$30.9M | -$52.2M | -$58.8M | -$43.4M | -$54.6M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | -100.0% | ||||||
| Crecimiento Beneficio Neto (anual) | -304.5% | -329.1% | -78.2% | -5.6% | +25.8% | -40.7% | |
| Crecimiento BPA (anual) | -298.4% | -156.7% | -48.1% | -4.4% | +26.1% | -38.6% | |
| Cambio en Acciones (anual) | +0.0% | +69.0% | +21.3% | +0.5% | +1.1% | +1.3% | |
| Crecimiento FCF (anual) | -6191.4% | -253.5% | -69.0% | -12.6% | +26.1% | -25.6% | |
| Margen Bruto | -98.3% | ||||||
| Margen Operativo | -228777.0% | ||||||
| Margen EBITDA | -16666.7% | ||||||
| Margen Neto | -245443.6% | ||||||
| Margen FCF | -16666.7% | ||||||
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.01 | $-0.32 | $-0.67 | $-0.94 | $-1.05 | $-0.77 | $-0.95 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $27.2M | $27.2M | $45.9M | $55.7M | $56.0M | $56.6M | $57.3M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -34.03% |
| Rentabilidad sobre capital invertido | -38.92% |
| Rentabilidad sobre activos | -32.91% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.01 |
| Ratio corriente | 18.86 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P/E | -551.00 | -138.30 | -27.81 | -9.00 | -2.23 | -7.01 | -7.69 |
| P/VC | -309.75 | -99.70 | 2.57 | 1.75 | 0.53 | 1.44 | 2.53 |
| P/V | 1352653.60 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | -98.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | -228777.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | -245443.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: ALT · ANNX · AURA · DMAC · ENGN · GALT · IMAB
Explorar sector: Healthcare · Biotechnology
Más secciones de DSGN: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones